weight loss response to semaglutide in postmenopausal women Frontiers GLP-1s + MHT: A Power

In clinical trials: Semaglutide: Approximately 7% discontinued due to adverse events Tirzepatide: Approximately 4-7% discontinued due to adverse events (dose dependent) Retatrutide: Approximately 6-10% discontinued due to adverse events (dose dependent) These rates are relatively close, suggesting that despite the differences in mechanism and side effect profiles, all three medications are tolerable for the vast majority of people who start them

The dose for weight loss is usually lower than the dose used for diabetes management

If unwanted weight gain occurs off treatment, they can restart Semaglutide injections at any time.

Dark yellow suggests drinking more